Nikhil C. Munshi MD
Adjunct Associate Professor, Hematology & Medical Oncology
72 E. Concord Street nikhil.munshi@va.gov
Sections
Hematology & Medical Oncology
Biography
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Education
MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University
Publications
Alsina M, Shah N, Jagannath S, Kaufman JL, Siegel D, Munshi NC, Rosenblatt J, Lin Y, Jakubowiak AJ, Derman BA, Li A, Mao P, Fincker M, Yeri A, Martin N, Campbell TB, Finney O, Truppel-Hartmann A, Petrocca F, Berdeja JG, Raje N. Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542. PMID: 41562447.
Published on 3/26/2026Maura F, Samur M, Munshi N. Evolution of multiple myeloma from a genomic perspective. Blood. 2026 Mar 26; 147(13):1423-1432. PMID: 41359792.
Published on 2/18/2026Moravej H, Rakhshandehroo T, Khan RMM, Rivet VM, Marcandalli E, Mantri SR, Taklifi P, Lee UJ, Louis BBV, Munaretto LA, Regan K, Farkash Z, Berland L, Gabr Z, Wolff AN, Kowalewski A, Allen HH, Nili A, Baral J, Mercadante D, Fulciniti M, Jacobson CA, Sperling AS, Nadeem O, Nia HT, Hemann M, Munshi NC, Rashidian M. Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Ra. J Immunother Cancer. 2026 Feb 18; 14(2). PMID: 41708145.
Published on 2/3/2026Du T, Fang T, Pillai SC, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC. Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma. Blood. 2026 Feb 03. PMID: 41632828.
Published on 1/16/2026Li C, Yang X, Shan J, Dickerson KA, Springer NA, Munshi NC, Batey RT, Disney MD. Mechanistically Defined Epoxide- and Aziridine-2-carboxamide Electrophiles Enable Stereoselective Covalent RNA Modulation. bioRxiv. 2026 Jan 16. PMID: 41648509.
Published on 1/12/2026Fulciniti M, Yao Y, Perini T, Fong Ng J, Schavgoulidze A, Deng S, Cui J, Encinas Mayoral J, Ladisa F, Young RM, Epstein CB, White CM, Ott CJ, Gulla A, Matulis SM, Sperling AS, Morelli E, Boise LH, Binder M, Szalat R, Samur MK, Anderson KC, Munshi NC. ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood Cancer Discov. 2026 Jan 12; 7(1):129-141. PMID: 41104834.
Published on 12/11/2025Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. J Clin Oncol. 2026 Feb; 44(4):321-334. PMID: 41380103.
Published on 11/20/2025Ferri GM, Yildirim C, Do NV, Brophy MT, Munshi NC, Edwards CV, Fillmore NR. Moderate-Severe Thrombocytopenia Portends Poor Outcomes in Multiple Myeloma. EJHaem. 2025 Dec; 6(6):e70153. PMID: 41278511.
Published on 11/18/2025Pertesi M, Demangel D, Niroula A, Perrial E, Mahecha Escobar ML, Vallée M, Liacos C, Samur MK, Sperling AS, Munshi NC, Kastritis E, Dimopoulos MA, McKay JD, Mellqvist UH, Hansson M, Dumontet C, Nilsson B. Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases. Leukemia. 2026 Jan; 40(1):235-240. PMID: 41254116.
Published on 11/13/2025Rivera J, Yan Q, Daneshmandi S, Lannes R, Katsuta E, Choi J, Singh P, Belal A, Alberico R, Lund I, Schaefer M, Hassan H, Parker S, Anderson KC, Munshi NC, Samur M, McCarthy PL, Hillengass J, Mohammadpour H. Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma. Blood. 2025 Nov 13; 146(20):2392-2405. PMID: 40758944.